Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Zillow Group Inc Class A — how do they compare? Vertex Pharmaceuticals Incorporated trades at $529.09 (market cap $134.25B), while Zillow Group Inc Class A trades at $32.94 (market cap $7.68B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 17.5× Zillow Group Inc Class A's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Zillow Group Inc Class A nearer its low. Which is the better fit depends on your goals.
| VRTX | ZG | |
|---|---|---|
Market Cap | $134.25B | $7.68B |
Sector | Health | Media |
52-Week High | $529.65 | $86.76 |
52-Week Low | $376.62 | $29.14 |
Enterprise Value | $128.37B | $7.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Zillow Group (ZG) trades at $34.07, up 0.35% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with 2025 revenue of $2.58B and a return to profitability ($23M net income) after years of losses. However, valuation remains elevated with a P/E of 149, while multiple class action lawsuits create near-term uncertainty. The stock faces resistance at $35 with support at $33.
ZG presents a mixed investment case with strong revenue growth and business model transition offset by legal overhangs and high valuation. The preferred agent model drives monetization improvement, but the stock requires careful risk management given the legal proceedings and technical bearish signals. Upside exists to the $47.56 consensus target if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
